General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Half-Life (Normalesrd) Hours
35/Unchanged
Plasma Protein Binding %
80-85
Volume Of Distribution L/Kg
21.5
Dose For Normal Renal Function
60-75 mg/m2 q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [B]
References
Benjamin RS, Riggs CE Jr, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res. 1977; 37: 1416-20. [PMID: 856462] / Goto M, Yoshida H, Honda A, Kumazawa T, Ohbayashi T, Inagaki J, et al. Delayed disposition of adriamycin and its active metabolite in haemodialysis patients [Letter]. Eur J Clin Pharmacol. 1993; 44: 301-2. [PMID: 8491250] / Robert J, Gianni L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv. 1993; 17: 219-52. [PMID: 8137342] / Yoshida H, Goto M, Honda A, Nabeshima T, Kumazawa T, Inagaki J, et al. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis. Cancer Chemother Pharmacol. 1994; 33: 450-4. [PMID: 8137454]
Toxicity Notes
Acute renal failure and nephrotic syndrome rare. Cardiotoxic with congestive heart failure and prerenal azotemia.